Skip to main content

Osteoarthritis (OA)

1
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
LRX712Phase 21 trial
Active Trials
NCT04097379Completed45Est. Jan 2025
Biocorp
BiocorpFrance - Issoire
1 program
GID SVF-2N/A1 trial
Active Trials
NCT02726945Completed39Est. Oct 2019
GID Bio
GID BioCO - Louisville
1 program
GID SVF-2N/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozLRX712
BiocorpGID SVF-2

Clinical Trials (2)

Total enrollment: 84 patients across 2 trials

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA

Start: Jul 2020Est. completion: Jan 202545 patients
Phase 2Completed

Adipose-derived SVF for the Treatment of Knee OA

Start: Apr 2016Est. completion: Oct 201939 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.